http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2013009091-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1023880af10dbe26a57dfb1cb687f92d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2012-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b1f6d14e9a13b85e15bf3963c63cf1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_650a21cfd9053e902445f310889147f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd8044cdcdead9ee04ce3c1a37a06977 |
| publicationDate | 2014-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2013009091-A |
| titleOfInvention | INHIBITORS OF THE PHOSPHODYDIC ACID PHOSFOHIDROLASA (PAP) ENZYMES, WHICH INCLUDE D-PROPANOLOL AND ANALOGS OF THE SAME, ONLY OR IN COMBINATION WITH DESIPRAMINE, FOR THE TREATMENT OF CANCERES THAT DEPEND ON THE EFFICIENT GROWTH AND EFFICIENT GROWTH ONCE (EPIDERMENTRENT) OF YOUR ERBB / HER FAMILY. |
| abstract | The present invention describes the use of compounds and combinations thereof that inhibit the phosphoric acid phosphohydrolase (PAP) enzyme for the formulation of medicaments useful in the treatment of cancer; PAP inhibitors are used to block the progression of epidermal growth factor receptor-dependent (EGFR) cancers, their oncogenic variants and other members of the ErbB family, through the induction of their endocytosis, making them inaccessible to stimuli that promote the maintenance and progression of cancer; Among the PAP inhibitors that are part of the invention are drugs for clinical use for other purposes and not related to each other, except for corresponding to amphiphilic cationic molecules; these include propranolol, desipramine, and chlorpromazine, drugs used in the clinic for other purposes; The present invention encompasses all PAP inhibitors, including sphingosine and Bremophenol lactone and all new inhibitors that may appear in the future. |
| priorityDate | 2011-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.